Cingulate (CING) Net Cash Flow (2021 - 2025)
Cingulate's (CING) quarterly Net Cash Flow came in at $4.8 million in Q4 2025, up 122.68% YoY from $2.2 million in Q4 2024, and up 279.57% on a QoQ basis from -$2.7 million in Q1 2025.
Cingulate (CING) Net Cash Flow (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Net Cash Flow data on file, last reported at $4.8 million in Q4 2025.
- Quarterly Net Cash Flow rose 122.68% year-over-year to $4.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (down 82.38% YoY) and the FY2025 annual result came in at -$1.3 million, down 110.35% from the prior year.
- Net Cash Flow grew to $4.8 million in Q4 2025, from -$2.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $14.6 million in Q4 2021 to a low of -$4.4 million in Q4 2022.
- A 5-year average of $730887.1 and a median of -$76678.5 in 2021 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 1971.64% — and 2024, when it surged 490.24%.
- Tracing CING's Net Cash Flow over 5 years: stood at $14.6 million in 2021, then slumped by 130.45% to -$4.4 million in 2022, then soared by 56.44% to -$1.9 million in 2023, then surged by 212.27% to $2.2 million in 2024, then surged by 122.68% to $4.8 million in 2025.
- The last three Net Cash Flow figures came in at $4.8 million (Q4 2025), -$2.7 million (Q1 2025), and $2.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Cingulate | 72.52 Mn | 72.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Mar 31, 2025 | -2.69 Mn |
| Mar 31, 2025 | -2.69 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Sep 30, 2024 | 9.66 Mn |
| Sep 30, 2024 | 9.66 Mn |
| Jun 30, 2024 | -732,903.00 |
| Jun 30, 2024 | -732,903.00 |
| Mar 31, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | -1.93 Mn |
| Dec 31, 2023 | -1.93 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | -1.39 Mn |
| Jun 30, 2023 | -1.39 Mn |
| Mar 31, 2023 | -3.62 Mn |
| Mar 31, 2023 | -3.62 Mn |